Skip to content
Comparison

Survodutide vs Semaglutide

Survodutide (BI 456906, Boehringer Ingelheim) and semaglutide (Ozempic/Wegovy, Novo Nordisk) represent two distinct approaches to GLP-1-based metabolic therapy. Semaglutide is a selective GLP-1 receptor agonist — the current gold standard — with FDA approval for both obesity and type 2 diabetes, SELECT cardiovascular outcomes data, and years of real-world use. Survodutide is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials, showing approximately 19% weight loss in Phase 2 vs. semaglutide's ~15%, with dramatically superior liver fat reduction via glucagon-mediated hepatic fat oxidation — a unique advantage for patients with MASH.

4.3(112 ratings)

Quick Answer

Survodutide achieves roughly 19% body weight loss vs. semaglutide's ~15% by adding glucagon receptor activation to GLP-1 — attacking obesity through both appetite suppression and increased energy expenditure. Survodutide shows superior liver fat reduction (up to 87%), making it the leading candidate for MASH. Semaglutide is FDA-approved with proven cardiovascular benefits; survodutide remains investigational. Choose semaglutide for proven treatment now; watch survodutide for potential best-in-class MASH or weight loss results.

Head-to-Head Comparison

CriteriaSurvodutideSemaglutide
Primary mechanismDual GLP-1 + glucagon receptor agonistSelective GLP-1 receptor agonist
Developer / brand nameBoehringer Ingelheim + Zealand Pharma (BI 456906) — no brand name yetNovo Nordisk — Ozempic (T2D), Wegovy (obesity), Rybelsus (oral)
FDA approval statusNot FDA-approved — Phase 3 trials ongoing (SYNCHRONIZE program)FDA-approved: Ozempic (2017), Wegovy (2021), Rybelsus oral (2019)
Average weight loss~18.7% body weight at 46 weeks (Phase 2, 6.0 mg dose)~15–17% body weight at 68 weeks (STEP-1, Wegovy 2.4 mg)
Liver fat reduction (MASH)Up to 87% relative reduction; MASH resolution in 83% of Phase 2 patientsModerate hepatic fat reduction — secondary to weight loss; no dedicated MASH approval
Energy expenditure effectIncreased resting energy expenditure via glucagon receptor activationMinimal direct effect — weight loss primarily from appetite suppression
Cardiovascular outcomes dataNo completed cardiovascular outcomes trialSELECT trial: 20% reduction in MACE in overweight/obese patients without diabetes
Injection frequencyOnce weekly (subcutaneous injection)Once weekly (subcutaneous injection); Rybelsus is daily oral
Oral formulationNo — injectable onlyYes — Rybelsus oral tablet (lower efficacy than injectable)
GI side effectsNausea 45–60%, diarrhea 28–35%, vomiting 22–30% at highest dosesNausea 44%, diarrhea 30%, vomiting 24% (Wegovy STEP-1 data)
Unique risksHeart rate increase (~4–8 bpm), transient early-titration glucose variability (glucagon effects)Well-characterized: pancreatitis class risk, thyroid C-cell caution, gallbladder events
Approximate monthly costNot commercially available$1,350/month list price (Wegovy); $200–$500 compounded semaglutide

When to Choose Each

Choose Survodutide

Patients with obesity + MASH who need hepatic fat reduction, those seeking maximum weight loss beyond semaglutide's ceiling, or patients interested in glucagon-mediated energy expenditure benefits — pending Phase 3 approval

Choose Semaglutide

Patients seeking proven, available, FDA-approved weight loss or T2D therapy; those needing cardiovascular risk reduction (SELECT data); anyone wanting oral option (Rybelsus); patients needing insurance coverage and established prescribing guidelines

Verdict

Semaglutide is the clear choice for patients who need a proven, FDA-approved therapy today. It has the strongest evidence base, multiple approved formulations, SELECT cardiovascular outcomes data, and years of real-world safety surveillance. Survodutide is the more compelling option for patients with concurrent MASH/fatty liver disease — where glucagon-driven hepatic fat oxidation provides a direct mechanistic advantage that GLP-1 alone cannot replicate. If Phase 3 results confirm Phase 2 data (~19% weight loss), survodutide could compete with tirzepatide in efficacy and potentially become the preferred agent specifically for obesity-with-MASH — a large, underserved population that semaglutide does not fully address. For now, survodutide is for those researching future treatment options, not a choice available today.

References

  1. Survodutide, a dual glucagon/GLP-1 receptor agonist, for people with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial (2023) — PubMed
  2. Efficacy and safety of survodutide in patients with NASH/MASH: a phase 2, randomised, double-blind, placebo-controlled trial (2024) — PubMed
  3. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with overweight or obesity without diabetes (SELECT trial) (2023) — PubMed
  5. BI 456906: a novel glucagon/GLP-1 receptor co-agonist — pharmacological characterization and first-in-human data (2022) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Is survodutide better than semaglutide (Ozempic) for weight loss?
Phase 2 data suggests survodutide achieves ~18.7% weight loss at 46 weeks vs. semaglutide's ~15% at 68 weeks — a meaningful difference if confirmed in Phase 3. However, cross-trial comparisons are inherently imperfect, and semaglutide was measured over a longer duration which may narrow the gap. Survodutide's glucagon receptor adds a genuine mechanistic advantage (energy expenditure), but semaglutide is available now with proven safety, SELECT cardiovascular data, and real-world evidence from millions of patients. Head-to-head Phase 3 trials are not planned.
What is the difference between survodutide and semaglutide?
Semaglutide is a selective GLP-1 receptor agonist that primarily reduces appetite and slows gastric emptying. Survodutide is a dual GLP-1/glucagon receptor agonist — it includes the same GLP-1 mechanism but adds glucagon receptor activation, which increases energy expenditure, promotes liver fat oxidation, and drives thermogenesis. This means survodutide attacks obesity from both sides: reducing caloric intake (GLP-1) and increasing caloric expenditure (glucagon). The practical consequence is more weight loss and dramatically superior liver fat reduction, particularly relevant for MASH patients.
Is survodutide safer than semaglutide?
Semaglutide has a significantly larger safety database: FDA approval since 2017, SELECT CVOT with ~17,000 participants, and millions of real-world patients across Ozempic and Wegovy. Survodutide's Phase 2 trials involved hundreds of patients over 46 weeks — far less safety data. Survodutide also adds glucagon-specific effects (heart rate elevation, early glucose variability) absent in semaglutide. Phase 3 trials will provide substantially more safety data, but survodutide will likely require several more years of post-market surveillance before its long-term safety profile matches semaglutide's documented record.
Can survodutide be used for MASH (metabolic liver disease)?
Survodutide is being specifically developed for MASH in Phase 3. Phase 2 MASH trial data showed 83% MASH resolution, 52% fibrosis improvement, and up to 87% liver fat reduction — results that far exceed what semaglutide achieves in MASH. If Phase 3 results are confirmed, survodutide could become the first GLP-1-class drug approved specifically for MASH, representing a major milestone. Semaglutide has no approved MASH indication and its hepatic effects are largely secondary to systemic weight loss rather than direct glucagon-driven mechanisms.
Is survodutide the same as Ozempic or Wegovy?
No — survodutide (BI 456906) and semaglutide (Ozempic/Wegovy) are different drugs with different molecular structures and different receptor targets. Ozempic and Wegovy are brand names for semaglutide — a selective GLP-1 receptor agonist by Novo Nordisk. Survodutide is Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist, developed in partnership with Zealand Pharma. The two share GLP-1 receptor agonism as a common mechanism but are distinct compounds with different receptor profiles, different developers, and different clinical trial evidence bases.
When will survodutide vs semaglutide head-to-head data be available?
Currently, no published head-to-head trial comparing survodutide directly to semaglutide exists. Phase 3 SYNCHRONIZE trials are placebo-controlled, not comparator-controlled against semaglutide or other GLP-1 agents. Head-to-head comparative effectiveness data may eventually emerge from post-approval real-world studies or investigator-initiated trials, but this is speculative. The best currently available comparison is indirect — Phase 2 survodutide data vs. Phase 3 semaglutide data — which has inherent methodological limitations and should be interpreted cautiously.

Explore next